Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages

Kamada Ltd. (NASDAQ:KMDA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Analysts have set a 12-month consensus target price of $8.50 for the company and are predicting that the company will post $0.04 EPS for the current quarter, according to Zacks. Zacks has also assigned Kamada an industry rank of 111 out of 265 based on the ratings given to its competitors.

Several brokerages have weighed in on KMDA. Zacks Investment Research lowered shares of Kamada from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 16th. Jefferies Group LLC restated a “buy” rating and set a $7.00 target price on shares of Kamada in a research report on Thursday, October 12th. ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, TheStreet lowered shares of Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st.

Several hedge funds have recently added to or reduced their stakes in KMDA. Jane Street Group LLC acquired a new stake in shares of Kamada in the third quarter valued at approximately $112,000. Worth Venture Partners LLC acquired a new stake in shares of Kamada in the third quarter valued at approximately $246,000. Edmond DE Rothschild Holding S.A. grew its position in shares of Kamada by 10.5% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 4,000 shares during the last quarter. Navellier & Associates Inc acquired a new stake in shares of Kamada in the second quarter valued at approximately $303,000. Finally, Analyst IMS Investment Management Services Ltd. lifted its stake in shares of Kamada by 125.5% during the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after buying an additional 50,000 shares during the period. Institutional investors and hedge funds own 6.94% of the company’s stock.

WARNING: “Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages” was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/11/21/kamada-ltd-kmda-given-8-50-average-target-price-by-brokerages.html.

Shares of Kamada (KMDA) traded up $0.05 during trading on Tuesday, hitting $4.70. 34,328 shares of the stock were exchanged, compared to its average volume of 71,949. Kamada has a twelve month low of $3.75 and a twelve month high of $8.61. The company has a current ratio of 3.71, a quick ratio of 2.73 and a debt-to-equity ratio of 0.02.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply